The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide

Pulmonary Pharmacology and Therapeutics - Tập 28 - Trang 114-121 - 2014
Amadeu Gavaldà1, Israel Ramos1, Carla Carcasona1, Elena Calama1, Raquel Otal1, José Luis Montero1, Sonia Sentellas1, Monica Aparici1, Dolors Vilella1, Joan Alberti1, Jorge Beleta1, Montserrat Miralpeix1
1Almirall R&D Centre, Laureà Miró, 408-410, 08980 Sant Feliu de Llobregat, Barcelona, Spain

Tài liệu tham khảo

Vestbo, 2013, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary, Am J Respir Crit Care Med, 187, 347, 10.1164/rccm.201204-0596PP

Gosens, 2006, Muscarinic receptor signaling in the pathophysiology of asthma and COPD, Respir Res, 7, 73, 10.1186/1465-9921-7-73

Canning, 2006, Reflex regulation of airway smooth muscle tone, J Appl Physiol, 101, 971, 10.1152/japplphysiol.00313.2006

Rogers, 2001, Motor control of airway goblet cells and glands, Respir Physiol, 125, 129, 10.1016/S0034-5687(00)00209-7

Rogers, 2002, Pharmacological regulation of the neuronal control of airway mucus secretion, Curr Opin Pharmacol, 2, 249, 10.1016/S1471-4892(02)00146-7

Barnes, 1992, Rationale for the use of antimuscarinics in obstructive airway disease, Rev Contemp Pharmacother, 3, 173

Barnes, 1993, Muscarinic receptor subtypes in airways, Life Sci, 52, 521, 10.1016/0024-3205(93)90310-Y

Roffel, 1990, Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle, Pulm Pharmacol, 3, 47, 10.1016/0952-0600(90)90009-8

Fisher, 2004, Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors, FASEB J, 18, 711, 10.1096/fj.03-0648fje

Tobin, 2006, Distribution and function of muscarinic receptor subtypes in the ovine submandibular gland, J Appl Physiol, 100, 1215, 10.1152/japplphysiol.00779.2005

National Institute for Health and Clinical Excellence, 2010

Barr, 2006, Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis, Thorax, 61, 854, 10.1136/thx.2006.063271

van Noord, 2000, A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group, Thorax, 55, 289, 10.1136/thorax.55.4.289

Ogale, 2010, Cardiovascular events associated with ipratropium bromide in COPD, Chest, 137, 13, 10.1378/chest.08-2367

Singh, 2008, Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis, JAMA, 300, 1439, 10.1001/jama.300.12.1439

Singh, 2011, Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials, BMJ, 342, d3215, 10.1136/bmj.d3215

European Medicines Agency, 2013

Novartis, 2012

Food and Drug Administration, 2012

Gavaldà, 2009, Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile, J Pharmacol Exp Ther, 331, 740, 10.1124/jpet.109.151639

Casarosa, 2009, Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs, J Pharmacol Exp Ther, 330, 660, 10.1124/jpet.109.152470

Sentellas, 2010, Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites, Eur J Pharm Sci, 39, 283, 10.1016/j.ejps.2010.01.004

Cheng, 1973, Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction, Biochem Pharmacol, 22, 3099, 10.1016/0006-2952(73)90196-2

Cortijo, 1994, The effects of phorbol 12,13-diacetate on responses of guinea-pig isolated trachea to methylxanthines, isoprenaline and ryanodine, Br J Pharmacol, 111, 769, 10.1111/j.1476-5381.1994.tb14804.x

Haddad, 1999, Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways, Br J Pharmacol, 127, 413, 10.1038/sj.bjp.0702573

Disse, 1993, Ba 679 BR, a novel long-acting anticholinergic bronchodilator, Life Sci, 52, 537, 10.1016/0024-3205(93)90312-Q

Tashkin, 2008, A 4-year trial of tiotropium in chronic obstructive pulmonary disease, N Engl J Med, 359, 1543, 10.1056/NEJMoa0805800

Casaburi, 2002, A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease, Eur Respir J, 19, 217, 10.1183/09031936.02.00269802

Kerwin, 2012, Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I), COPD, 9, 90, 10.3109/15412555.2012.661492

Jones, 2012, Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study, Eur Respir J, 40, 830, 10.1183/09031936.00225511

Kerwin, 2012, Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study, Eur Respir J, 40, 1106, 10.1183/09031936.00040712

D'Urzo, 2011, Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial, Respir Res, 12, 156, 10.1186/1465-9921-12-156

Beeh, 2011, Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD, COPD, 8, 340, 10.3109/15412555.2011.594464

Sykes, 2012, The influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium, J Pharmacol Exp Ther, 343, 520, 10.1124/jpet.112.194456

Brodde, 1999, Adrenergic and muscarinic receptors in the human heart, Pharmacol Rev, 51, 651

Verkindre, 2010, Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients, Respir Med, 104, 1482, 10.1016/j.rmed.2010.04.006

Fuhr, 2012, Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD, Chest, 141, 745, 10.1378/chest.11-0406

Jansat, 2009, Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants, J Clin Pharmacol, 49, 1239, 10.1177/0091270009336353

Jansat, 2009, Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects, Int J Clin Pharmacol Ther, 47, 460, 10.5414/CPP47460

Thông tin
Thông tin xuất bản

Pulmonary Pharmacology and Therapeutics

Tập 28

114-121

Thông tin tác giả